Solventum Corporation
SOLV Healthcare Medical - Care Facilities NYSE
$69.41
$-1.37 (-1.94%)
Open: $69.74 | High: $70.43 | Low: $68.99 | Prev Close: $70.78
Market Cap: $12.04B
Volume: 1.0M | Avg: 1.1M
Last updated: March 09, 2026 at 02:04 AMFeatured In
This stock appears in the following dashboards:
Options Activity for SOLV
Options Screener Data
| Type | Strike | Expiration | Premium | Premium Yield | Call Vol | Put Vol | P/C Ratio | Rating |
|---|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A% | N/A | N/A | N/A | N/A/10 |
Puts/Calls Activity
| Type | Strike | Expiration | Premium | Volume | ROI % | Breakeven | Delta |
|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A | N/A% | $N/A | N/A |
Investment Rating
Buy
Overall Score: 80/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 547
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 7.97 |
| P/B Ratio | 2.39 |
| P/S Ratio | 1.45 |
| EPS | $8.71 |
| Beta | 0.54 |
| Shares Outstanding | 173.49M |
| 52-Week High | $88.20 |
| 52-Week Low | $60.70 |
| SMA 50 | $77.77 |
| SMA 200 | $75.35 |
| Next Earnings | May 06, 2026 10:59 AM ET |
Financial Ratios
| Gross Margin | 53.5% |
| Operating Margin | 26.2% |
| Net Margin | 18.7% |
| ROE | 36.7% |
| ROA | 10.9% |
| Debt/Equity | 1.00 |
| Current Ratio | 1.23 |
| Quick Ratio | 0.89 |
Balance Sheet
| Total Assets | $14.29B |
| Total Liabilities | $9.24B |
| Total Equity | $5.05B |
|
|
|
| Cash | $878.00M |
| Total Debt | $5.04B |
| Net Debt | $4.16B |
Income Statement
| Revenue | $8.32B |
| Gross Profit | $4.45B |
| Operating Income | $2.18B |
| Net Income | $1.56B |
|
|
|
| EBITDA | $2.55B |
| Revenue/Share | $47.82 |
Cash Flow
| Operating CF | $369.00M |
| CapEx | $379.00M |
| Free Cash Flow | $-10,000,000 |
|
|
|
| Book Value/Share | $29.00 |
| Tangible Book/Share | $-18.65 |
| Equity/Share | $29.00 |
Technical Indicators
| RSI (14) | 34.86 Neutral |
| MACD |
-1.93
Signal: -1.60
|
| Volatility | 35.65% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | -8.39% |
| Sharpe Ratio | -0.33 Poor |
| Volatility (Ann.) | 27.48% Moderate |
| SOLV (1Y) | -8.39% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -21.43% |
Sector Comparison (Healthcare)
| Metric | SOLV | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 7.97 | 28.03 | 8% |
| P/B Ratio | 2.39 | -19.57 | 40% |
| ROE (%) | 36.74% | -9.99% | 87% |
| Net Margin (%) | 18.69% | 9.14% | 74% |
| Stock Score | 547 | 543.0 | 49% |
| 1Y Return (%) | -8.39 % | +8.47 % | 29% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLV | $69.41 | $71.50 | $72.72 | $73.05 | $77.86 | $75.38 | 34.86 | -1.93 | 35.65% | 226572 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the SOLV stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| SOLV | Solventum to Participate in the 2026 KeyBanc Healthcare Forum | Neutral | prnewswire.com | Read More |
| SOLV | Solventum Corporation (NYSE:SOLV) Receives Average Rating of “Moderate Buy” from Analysts | Neutral | defenseworld.net | Read More |
| SOLV | Solventum (SOLV) is a Top-Ranked Value Stock: Should You Buy? | Neutral | zacks.com | Read More |
| SOLV | Solventum: Improvements Come Slow | Neutral | seekingalpha.com | Read More |
| SOLV | Citigroup Inc. Decreases Holdings in Solventum Corporation $SOLV | Negative | defenseworld.net | Read More |
Recent Insider Trading
| Date | Insider | Position | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-10 | Wendell Amy McBride | director | BUY | 1475 | $68.03 | $100344 |
| 2026-03-06 | Landucci Amy | officer: Chief Information Officer | SELL | 1731 | $69.41 | $120149 |
| 2026-03-06 | Harrington Paul S | officer: Chief Supply Chain Officer | SELL | 1073 | $69.41 | $74477 |
| 2026-03-06 | McMillan Wayde D. | officer: Chief Financial Officer | SELL | 2786 | $69.41 | $193376 |
| 2026-03-06 | Gomez Tammy L | officer: Chief Human Resources Officer | SELL | 895 | $69.41 | $62122 |
| 2026-03-06 | Hanson Bryan C | director, officer: Chief Executive Officer | SELL | 10395 | $69.41 | $721517 |
| 2026-03-06 | Kirberger Marcela A. | officer: Chief Legal Affairs Officer | SELL | 1232 | $69.41 | $85513 |
Company Information
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
| CEO | Bryan C. Hanson |
| Employees | 22000 |
| Country | US |
| IPO Date | 2024-04-01 |
| Exchange | NYSE |
| Website | https://www.solventum.com |
| Sector | Healthcare |
| Industry | Medical - Care Facilities |
Similar Stocks (Healthcare - Medical - Care Facilities)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category